Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

62.04
+2.303.85%
Post-market: 62.120.0815+0.13%18:57 EDT
Volume:2.21M
Turnover:135.49M
Market Cap:10.31B
PE:-17.83
High:62.07
Open:60.54
Low:59.70
Close:59.74
52wk High:86.74
52wk Low:41.71
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.84
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:23.45
PE(LYR):-26.05

Loading ...

Ionis Pharmaceuticals price target lowered to $108 from $110 at TD Cowen

TIPRANKS
·
Apr 23

Earning Preview: Ionis Pharmaceuticals Q1 revenue is expected to increase by 56%, and institutional views are bullish

Earnings Agent
·
Apr 23

How Zilganersen’s Positive Pivotal Data and FDA Priority Review Could Impact Ionis Pharmaceuticals (IONS) Investors

Simply Wall St.
·
Apr 23

H.C. Wainwright Remains a Buy on Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Apr 22

Ionis Pharmaceuticals Initiated at Buy by Canaccord Genuity

Dow Jones
·
Apr 21

Ionis Pharmaceuticals price target raised to $130 from $95 at Morgan Stanley

TIPRANKS
·
Apr 21

Ionis Pharmaceuticals Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Apr 21

This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains. -- Barrons.com

Dow Jones
·
Apr 21

Ionis announces additional results from zilganersen study in AxD

TIPRANKS
·
Apr 21

BRIEF-Ionis Pharmaceuticals Inc - Zilganersen 50 Mg Meets Primary Endpoint, Stabilizes Gait Speed In Patients ≥5 Years At Week 61

Reuters
·
Apr 21

Canaccord Genuity Initiates Coverage on Ionis Pharmaceuticals With Buy Rating, $110 Price Target

MT Newswires Live
·
Apr 21

Ionis Pharmaceuticals Inc - Zilganersen Under FDA Priority Review With Pdufa Date Set for September 22, 2026

THOMSON REUTERS
·
Apr 21

Ionis Pharmaceuticals Inc - Key Secondary Endpoint Results Consistently Favored Zilganersen Over Control

THOMSON REUTERS
·
Apr 21

Ionis says zilganersen trial in Alexander disease meets primary endpoint on gait speed

Reuters
·
Apr 21

Ionis Pharmaceuticals initiated with a Buy at Canaccord

TIPRANKS
·
Apr 21

Ionis EVP Kyle Jenne disposes of 4,902 shares worth $368,683.54

Reuters
·
Apr 18

Ionis director B. Lynne Parshall sells USD 381,702 in common shares

Reuters
·
Apr 18

Ionis EVP Brian Birchler disposes of USD 73,020 Ionis common shares

Reuters
·
Apr 18

Ionis EVP, Chief Business Officer Joseph Baroldi disposes 5,619 shares for $418,356.64

Reuters
·
Apr 18